Herceptin Combinations for Advanced Breast Cancer The FDA approved Perjeta ® (pertuzumab) for the treatment of HER2-positive, metastatic breast cancer in combination with Herceptin ® (trastuzumab) and docetaxel chemotherapy in patients who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.
Categories